Reply to correspondence on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C” Chen-Hua Liu, Yu-Ping Chang Clinical and Molecular Hepatology.2025; 31(2): e232. CrossRef
Background/Aims Direct-acting antivirals (DAAs) effectively eradicate hepatitis C virus. This study investigated whether metabolic dysfunction influences the likelihood of fibrosis regression after DAA treatment in patients with chronic hepatitis C (CHC).
Methods This multicenter, retrospective study included 8,819 patients diagnosed with CHC who were treated with DAAs and achieved a sustained virological response (SVR) between January 2014 and December 2022. Fibrosis regression was defined as a 20% reduction in noninvasive surrogates for liver fibrosis, such as liver stiffness (LS) measured by vibration-controlled transient elastography (VCTE) and the fibrosis-4 (FIB-4) score. Hypercholesterolemia (h-TC) was defined as >200 mg/dL.
Results The median age of the study population was 59.6 years, with a predominance of male patients (n=4,713, 57.3%). Genotypes 1, 2, and others were confirmed in 3,872 (46.2%), 3,487 (41.6%), and 1,024 (12.2%) patients, respectively. Diabetes mellitus (DM) was present in 1,442 (17.2%) patients and the median LS was 7.50 kPa (interquartile range, 5.30–12.50). Multivariate analysis revealed that the presence of DM and pre-DAA h-TC were independently associated with a decreased probability of fibrosis regression by VCTE. Additionally, pre-DAA h-TC was independently associated with a decreased probability of fibrosis regression by the FIB-4.
Conclusions Metabolic dysfunction has an unfavorable influence on fibrosis regression in patients with CHC who achieve SVR after DAA treatment.
Citations
Citations to this article as recorded by
Editorial: Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection—Authors' Reply Yu‐Ping Chang, Jia‐Horng Kao, Chen‐Hua Liu Alimentary Pharmacology & Therapeutics.2025; 61(9): 1553. CrossRef
Epidemiologic Characteristics of Chronic Hepatitis B and Coinfections with Hepatitis C Virus or Human Immunodeficiency Virus in South Korea: A Nationwide Claims-Based Study Using the Korean Health Insurance Review and Assessment Service Database Hyunwoo Oh, Won Sohn, Na Ryung Choi, Hyo Young Lee, Yeonjae Kim, Seung Woo Nam, Jae Yoon Jeong Pathogens.2025; 14(7): 715. CrossRef
The treatment of chronic hepatitis C (CHC) has been revolutionized in an era of all-oral direct-acting antivirals (DAAs) since 2014. Satisfactory treatment efficacy and tolerability can be provided by novel DAAs. Nevertheless, there are still some unmet needs and emerging issues in the treatment of CHC in the DAA era. Certain hard-to-cure populations are prone to have inferior treatment responses, including patients with severe liver decompensation, active hepatocellular carcinoma (HCC), and hepatitis C virus (HCV) genotype 3 (HCV-3) infection and those who experience multiple DAA treatment failures. Hepatitis B virus (HBV) reactivation during and after DAA treatment has raised concern regarding the use of prophylactic antivirals against HBV throughout DAA treatment. However, the standard strategy for the use of prophylactic antivirals is not uniform across regional guidelines. In the post-sustained virological response (SVR) period, HCC still occurs in a substantial proportion of patients. Due to the relatively short follow-up period, the net benefit of the achievement of an SVR by DAAs in the reduction of extrahepatic manifestations has not yet been determined. Attention must also be paid to HCV reinfection, particularly in high-risk populations. The most critical and unmet need for HCV elimination is the large gap in the HCV care cascade at the population level. To accomplish the World Health Organization (WHO)’s goal for HCV elimination by 2030, the expansion of access to HCV care requires a continuous effort to overcome practical and political challenges.
Citations
Citations to this article as recorded by
Real‐world efficacy and safety of universal 8‐week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre‐end‐stage renal disease: Insights from a nationwide hepatisis C virus registry in Taiwan Szu‐Jen Wang, Chung‐Feng Huang, Te‐Sheng Chang, Ching‐Chu Lo, Chao‐Hung Hung, Chien‐Wei Huang, Lee‐Won Chong, Pin‐Nan Cheng, Ming‐Lun Yeh, Cheng‐Yuan Peng, Chien‐Yu Cheng, Jee‐Fu Huang, Ming‐Jong Bair, Chih‐Lang Lin, Chi‐Chieh Yang, Hsing‐Tao Kuo, Tsai‐Yu The Kaohsiung Journal of Medical Sciences.2025;[Epub] CrossRef
Long-Term Risk of Hepatic and Extrahepatic-Related Events After Direct Antiviral Therapy for Chronic Hepatitis C: A Prospective Long-Term Study Cohort Luisa Cavalletto, Eleonora Bertoli, Claudia Mescoli, Camillo Aliberti, Maria Giovanna Quaranta, Loreta Kondili, Liliana Chemello Cancers.2025; 17(9): 1528. CrossRef
A Point‐of‐Care Model for Hepatitis C Elimination in Remote Islands of Taiwan Tzu‐Chun Lin, Pei‐Chien Tsai, Chung‐Feng Huang, Ming‐Lun Yeh, Yu‐Ju Wei, Ming‐Yen Hsieh, Ming‐Jong Bair, Chia‐Yen Dai, Jee‐Fu Huang, Ming‐Lung Yu, Wan‐Long Chuang The Kaohsiung Journal of Medical Sciences.2025;[Epub] CrossRef
HCV Genotype Distribution and Molecular Characteristics of HCV Core Domain I in Persons Living with HIV and HCV from Yunnan Province, China Yantao Zhu, Junyi Liu, Lijuan Kang, Fangchao Ruan, Jianjian Li, Nian Zhang, Yanling Chen, Zhiying Yao, Haihua Yang, Jun Leng, Jinglin Wang, Jiali Wang AIDS Research and Human Retroviruses.2025;[Epub] CrossRef
Toward hepatitis C virus elimination using artificial intelligence Moon Haeng Hur, Jeong-Hoon Lee Clinical and Molecular Hepatology.2024; 30(2): 147. CrossRef
Strategies of hepatitis C virus elimination for people who inject drugs receiving opioid agonist therapy in the era of direct‐acting antivirals Fai‐Meng Sou, Chien‐Hung Chen, Pao‐Yuan Huang, Ming‐Chao Tsai, Yi‐Hao Yen, Sheng‐Nan Lu, Chao‐Hung Hung, Yuan‐Hung Kuo Advances in Digestive Medicine.2024; 11(4): 189. CrossRef
Rapid appraisal of liver diseases using transient elastography, abdominal ultrasound, and microbiology in Côte d’Ivoire: A single-center study Marie T. Leibenguth, Jean T. Coulibaly, Kigbafori D. Silué, Yves K. N’Gbesso, Ahmed Abd El Wahed, Jürg Utzinger, Sören L. Becker, Sophie Schneitler, Alessandra Morassutti PLOS Neglected Tropical Diseases.2024; 18(6): e0012262. CrossRef
High efficacy and safety of direct‐acting antivirals for the treatment of chronic hepatitis C: A cohort study conducted in Vietnam Thong Duy Vo, Van Thi Thu Bui, Huong Tu Lam, Quynh Thi Huong Bui Pharmacology Research & Perspectives.2024;[Epub] CrossRef
The role of artificial intelligence in the management of liver diseases Ming‐Ying Lu, Wan‐Long Chuang, Ming‐Lung Yu The Kaohsiung Journal of Medical Sciences.2024; 40(11): 962. CrossRef
Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter? Carlo Smirne, Maria Grazia Crobu, Irene Landi, Nicole Vercellino, Daria Apostolo, David James Pinato, Federica Vincenzi, Rosalba Minisini, Stelvio Tonello, Davide D’Onghia, Antonio Ottobrelli, Silvia Martini, Christian Bracco, Luigi Maria Fenoglio, Mauro Viruses.2024; 16(12): 1899. CrossRef
Synthesis of novel azasugar-containing 2'β-C-Me 9-deaza nucleosides as potential anti-hepatitis C virus agents Pravin L. Kotian, Minwan Wu, Ajit Ghosh, Kevin J. Polach, Yahya El-Kattan, V. Satish Kumar, Tsu-Hsing Lin, Xiaogang Cheng, Shanta Bantia, Krishnan Raman, Pooran Chand, Yarlagadda S. Babu Nucleosides, Nucleotides & Nucleic Acids.2023; 42(4): 317. CrossRef
Micro-elimination of hepatitis C virus infection in the rural and remote areas of Taiwan – A multi-center collaborative care model Ching-Chu Lo, Wei-Yi Lei, Ying-Che Huang, Jow-Jyh Hwang, Chen-Yu Lo, Chien-hung Lin, Hsu-sheng Cheng, Yee-Tam Liao, Po-Cheng Liang, Meng-Jau Chiou, Ming-Jong Bair, Chia-Yen Dai, Ming-Lung Yu Journal of Microbiology, Immunology and Infection.2023; 56(4): 680. CrossRef
Gastrointestinal functional disorders can benefit from the use of medical devices made of substances Vincenzo Savarino, Elisa Marabotto, Patrizia Zentilin, Manuele Furnari, Giorgia Bodini, Edoardo Giovanni Giannini, Edoardo Vincenzo Savarino Frontiers in Drug Safety and Regulation.2023;[Epub] CrossRef
A people-centered decentralized outreach model toward HCV micro-elimination in hyperendemic areas: COMPACT study in SARS Co–V2 pandemic Ching-I Huang, Po-Cheng Liang, Yu-Ju Wei, Pei-Chien Tsai, Po-Yao Hsu, Ming-Yen Hsieh, Ta-Wei Liu, Yi-Hung Lin, Meng-Hsuan Hsieh, Tyng-Yuan Jang, Chih-Wen Wang, Jeng-Fu Yang, Ming-Lun Yeh, Chung-Feng Huang, Chia-Yen Dai, Wan-Long Chuang, Jee-Fu Huang, Ming Journal of Microbiology, Immunology and Infection.2023; 56(3): 586. CrossRef
Human Mesenchymal Stem Cells Modified with the NS5A Gene of Hepatitis C Virus Induce a Cellular Immune Response Exceeding the Response to DNA Immunization with This Gene Olga V. Masalova, Ekaterina I. Lesnova, Vladimir A. Kalsin, Regina R. Klimova, Natalya E. Fedorova, Vyacheslav V. Kozlov, Natalya A. Demidova, Kirill I. Yurlov, Mikhail A. Konoplyannikov, Tatyana N. Nikolaeva, Alexander V. Pronin, Vladimir P. Baklaushev, Biology.2023; 12(6): 792. CrossRef
A Vermont Statewide Educational Intervention to Improve Access to Hepatitis C Virus Treatment in a Rural State Andrew J. Hale, Steven D. Lidofsky Journal of Medical Education and Curricular Development.2023;[Epub] CrossRef
Liver Fibrosis Regression and Associated Factors in HCV Patients Treated with Direct-Acting Antiviral Agents Naim Abu-Freha, Osama Abu-Kosh, David Yardeni, Yaffa Ashur, Muhammad Abu-Arar, Baha Yousef, Shulamit Monitin, Sarah Weissmann, Ohad Etzion Life.2023; 13(9): 1872. CrossRef
Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program Ming-Ying Lu, Chung-Feng Huang, Chao-Hung Hung, Chi‐Ming Tai, Lein-Ray Mo, Hsing-Tao Kuo, Kuo-Chih Tseng, Ching-Chu Lo, Ming-Jong Bair, Szu-Jen Wang, Jee-Fu Huang, Ming-Lun Yeh, Chun-Ting Chen, Ming-Chang Tsai, Chien-Wei Huang, Pei-Lun Lee, Tzeng-Hue Yang Clinical and Molecular Hepatology.2023; 30(1): 64. CrossRef
Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels Po‐Yao Hsu, Tzu‐Sheng Cheng, Shih‐Chang Chuang, Wen‐Tsan Chang, Po‐Cheng Liang, Cheng‐Ting Hsu, Yu‐Ju Wei, Tyng‐Yuan Jang, Ming‐Lun Yeh, Ching‐I Huang, Yi‐Hung Lin, Chih‐Wen Wang, Ming‐Yen Hsieh, Nai‐Jen Hou, Meng‐Hsuan Hsieh, Yi‐Shan Tsai, Yu‐Min Ko, Chi Cancer Medicine.2022; 11(1): 104. CrossRef
Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison Chun-Ting Chen, Ming-Ying Lu, Meng-Hsuan Hsieh, Pei-Chien Tsai, Tsai-Yuan Hsieh, Ming-Lun Yeh, Ching-I Huang, Yi-Shan Tsai, Yu-Min Ko, Ching-Chih Lin, Kuan-Yu Chen, Yu-Ju Wei, Po-Yao Hsu, Cheng-Ting Hsu, Tyng-Yuan Jang, Ta-Wei Liu, Po-Cheng Liang, Ming-Ye World Journal of Gastroenterology.2022; 28(2): 263. CrossRef
Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwan Ching-Chu Lo, Chung-Feng Huang, Pin-Nan Cheng, Kuo-Chih Tseng, Chi-Yi Chen, Hsing-Tao Kuo, Yi-Hsiang Huang, Chi-Ming Tai, Cheng-Yuan Peng, Ming-Jong Bair, Chien-Hung Chen, Ming-Lun Yeh, Chih-Lang Lin, Chun-Yen Lin, Pei-Lun Lee, Lee-Won Chong, Chao-Hung Hu Journal of the Formosan Medical Association.2022; 121(8): 1567. CrossRef
Combination of dasabuvir and PSI-6206 for the treatment of coxsackievirus B3 infection Oluwatayo Israel Olasunkanmi, Zhao-Hua Zhong Journal of Virus Eradication.2022; 8(2): 100074. CrossRef
Milestones in the discovery of hepatitis C Octavio Campollo, Gerardo Amaya, P Aiden McCormick World Journal of Gastroenterology.2022; 28(37): 5395. CrossRef
A People-Centered Decentralized Outreach Model Toward HCV Micro-Elimination in Hyperendemic Areas: COMPACT Study in SARS Co-V2 Pandemic Ching-i Huang, Po-Cheng Liang, Yu-Ju Wei, Pei-Chien Tsai, Po-Yao Hsu, Ming-Yen Hsieh, Ta-Wei Liu, Yi-Hung Lin, Meng-Hsuan Hsieh, Tyng-Yuan Jang, Chih-Wen Wang, Jeng-Fu Yang, Ming-Lun Yeh, Chung-Feng Huang, Chia-Yen Dai, Wan-Long Chuang, Jee-Fu Huang, Ming SSRN Electronic Journal .2022;[Epub] CrossRef
Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C) Ming-Lung Yu, Chung-Feng Huang, Yu-Ju Wei, Wen-Yi Lin, Yi-Hung Lin, Po-Yao Hsu, Cheng-Ting Hsu, Ta Wei Liu, Jia-Jung Lee, Sheng-Wen Niu, Jiun-Chi Huang, Tzu-Sui Hung, Ming-Lun Yeh, Ching-I Huang, Po-Cheng Liang, Ming-Yen Hsieh, Szu-Chia Chen, Jee-Fu Huang Gut.2021; 70(12): 2349. CrossRef
Path from the discovery to the elimination of hepatitis C virus: Honoring the winners of the Nobel Prize in Physiology or Medicine 2020 Ming‐Lung Yu, Wan‐Long Chuang The Kaohsiung Journal of Medical Sciences.2021; 37(1): 7. CrossRef
Elbasvir and grazoprevir for the treatment of hepatitis C Szu-Jen Wang, Chung-Feng Huang, Ming-Lung Yu Expert Review of Anti-infective Therapy.2021; 19(9): 1071. CrossRef
Scaling up the in-hospital hepatitis C virus care cascade in Taiwan Chung-Feng Huang, Pey-Fang Wu, Ming-Lun Yeh, Ching-I Huang, Po-Cheng Liang, Cheng-Ting Hsu, Po-Yao Hsu, Hung-Yin Liu, Ying-Chou Huang, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu Clinical and Molecular Hepatology.2021; 27(1): 136. CrossRef
Drug-drug interactions with direct-acting antivirals — less is more Grace Lai-Hung Wong Clinical and Molecular Hepatology.2021; 27(1): 81. CrossRef
Outcomes of Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir in Mongolian Population: Successes and Challenges Facing Scale-up of Care Seong Hee Kang, Moon Young Kim Clinical and Molecular Hepatology.2021; 27(1): 100. CrossRef
The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients Yu Jun Wong, Prem Harichander Thurairajah, Rahul Kumar, Kwong Ming Fock, Ngai Moh Law, Sin-Yoong Chong, Fria Gloriba Manejero, Tiing-Leong Ang, Eng Kiong Teo, Jessica Tan Clinical and Molecular Hepatology.2021; 27(3): 474. CrossRef
Future outcomes and health needs of chronic hepatitis C patients after receiving antiviral therapy Yu‐Hsuan Hsiao, Wei‐Ming Chen, Chia‐Hao Chang, Mei‐Yen Chen Journal of Advanced Nursing.2021; 77(8): 3370. CrossRef
Achieving HCV micro-elimination in rural communities Shannon J Brown, Linh T Cosgrove, Samuel S Lee Canadian Liver Journal.2021; 4(1): 1. CrossRef
Factors associated with treatment failure of direct‐acting antivirals for chronic hepatitis C: A real‐world nationwide hepatitis C virus registry programme in Taiwan Chi‐Yi Chen, Chung‐Feng Huang, Pin‐Nan Cheng, Kuo‐Chih Tseng, Ching‐Chu Lo, Hsing‐Tao Kuo, Yi‐Hsiang Huang, Chi‐Ming Tai, Cheng‐Yuan Peng, Ming‐Jong Bair, Chien‐Hung Chen, Ming‐Lun Yeh, Chih‐Lang Lin, Chun‐Yen Lin, Pei‐Lun Lee, Lee‐Won Chong, Chao‐Hung Hu Liver International.2021; 41(6): 1265. CrossRef
Screening, confirmation, and treatment rates of hepatitis C virus infection in a tertiary academic medical center in South Korea Jae Seung Lee, Hong Jun Choi, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Journal of Gastroenterology and Hepatology.2021; 36(9): 2479. CrossRef
Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH) Ming-Lun Yeh, Chao-Hung Hung, Kuo-Chih Tseng, Hsueh-Chou Lai, Chi-Yi Chen, Hsing-Tao Kuo, Jing-Houng Wang, Jyh-Jou Chen, Pei-Lun Lee, Rong-Nan Chien, Chi-Chieh Yang, Gin-Ho Lo, Chi‐Ming Tai, Chih-Wen Lin, Jia-Horng Kao, Chen-Hua Liu, Sheng-Lei Yan, Ming-J Hepatology International.2021; 15(5): 1109. CrossRef
Differential Expression of the Host Lipid Regulators ANGPTL-3 and ANGPTL-4 in HCV Infection and Treatment Vaia Valiakou, Petros Eliadis, Eirini Karamichali, Ourania Tsitsilonis, John Koskinas, Urania Georgopoulou, Pelagia Foka International Journal of Molecular Sciences.2021; 22(15): 7961. CrossRef
In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet? Natalia Echeverría, Victoria Comas, Fabián Aldunate, Paula Perbolianachis, Pilar Moreno, Juan Cristina World Journal of Hepatology.2021; 13(10): 1234. CrossRef
Resistance-associated substitutions and response to treatment in a chronic hepatitis C virus infected-patient: an unusual virological response case report Fabián Aldunate, Natalia Echeverría, Daniela Chiodi, Pablo López, Adriana Sánchez-Cicerón, Martín Soñora, Juan Cristina, Gonzalo Moratorio, Nelia Hernández, Pilar Moreno BMC Infectious Diseases.2021;[Epub] CrossRef
Prior antiviral treatment and mortality among patients with hepatitis C virus-related hepatocellular carcinoma: A national cohort study Dong Hyun Sinn, Danbee Kang, Yun Soo Hong, Kwang Cheol Koh, Eliseo Guallar, Juhee Cho, Geum-Youn Gwak, Luca Rinaldi PLOS ONE.2021; 16(8): e0255624. CrossRef
Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan Chung-Feng Huang, Hsing-Tao Kuo, Te-Sheng Chang, Ching-Chu Lo, Chao-Hung Hung, Chien-Wei Huang, Lee-Won Chong, Pin-Nan Cheng, Ming-Lun Yeh, Cheng-Yuan Peng, Chien-Yu Cheng, Jee-Fu Huang, Ming-Jong Bair, Chih-Lang Lin, Chi-Chieh Yang, Szu-Jen Wang, Tsai-Yu Scientific Reports.2021;[Epub] CrossRef
Difluoromethylornithine (DFMO), an Inhibitor of Polyamine Biosynthesis, and Antioxidant N-Acetylcysteine Potentiate Immune Response in Mice to the Recombinant Hepatitis C Virus NS5B Protein Ekaterina I. Lesnova, Olga V. Masalova, Kristina Yu. Permyakova, Vyacheslav V. Kozlov, Tatyana N. Nikolaeva, Alexander V. Pronin, Vladimir T. Valuev-Elliston, Alexander V. Ivanov, Alla A. Kushch International Journal of Molecular Sciences.2021; 22(13): 6892. CrossRef
HCV RNA in serum and liver samples of patients undergoing living donor liver transplantation Shu-Hsien Lin, Kun-Ta Wu, Chih-Chi Wang, Kuang-Tzu Huang, Kuang-Den Chen, Chih-Che Lin, Li-Wen Hsu, King-Wah Chiu Journal of International Medical Research.2021;[Epub] CrossRef
Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Alex Thompson, Jidong Jia, Jinlin Hou, Cosmas Rinaldi Adithya Lesmana, Adityo Susilo, Yasuhito Tanaka, Wah-Kheong Chan, Ed Gane, Arlinking K Ong-Go, Seng-Gee Lim, Sang Hoon Ahn, Ming-Lung Yu, Teerha Piratvisuth, The Lancet Gastroenterology & Hepatology.2020; 5(8): 776. CrossRef
Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals Sara Kishta, Ashraf Tabll, Tea Omanovic Kolaric, Robert Smolic, Martina Smolic Biomedicines.2020; 8(6): 175. CrossRef
High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy Wei-Ming Chen, Kuo-Liang Wei, Shui-Yi Tung, Chien-Heng Shen, Te-Sheng Chang, Chih-Wei Yen, Yung-Yu Hsieh, Wen Nan Chiu, Jin Hung Hu, Sheng-Nan Lu, Chao-Hung Hung Journal of the Formosan Medical Association.2020; 119(11): 1593. CrossRef
Infectious diseases of the hepatobiliary system Rachel Mary Brown Diagnostic Histopathology.2020; 26(12): 566. CrossRef
Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals Hye Won Lee, Dai Hoon Han, Hye Jung Shin, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Cancers.2020; 12(11): 3414. CrossRef
Nadia Marascio, Angela Quirino, Giorgio Settimo Barreca, Luisa Galati, Chiara Costa, Vincenzo Pisani, Maria Mazzitelli, Giovanni Matera, Maria Carla Liberto, Alfredo Focà, Carlo Torti
Clin Mol Hepatol 2019;25(1):30-36. Published online January 23, 2019
Hepatitis C virus (HCV) infects around 71 million people worldwide and in 2018 it is still a major health problem. Since 2011, anti-HCV therapy with availability of direct-acting antiviral drugs has revolutionized the clinical response and paved the way to eradication strategies. However, despite the high rate of sustained virological response, treatment failure may occur in a limited percentage of patients, possibly due to resistance-associated substitutions (RASs), either emergent or pre-existent even in minority viral populations. Clearly this problem may impair success of eradication strategies. With this background, several questions marks still exist around HCV treatment, including whether pan-genotypic treatments with complete effectiveness in any clinical conditions really exist outside clinical trials, the actual cost-effectiveness of genotyping testing, and utility of RAS detection in viral quasispecies by next generation sequencing approach. In this review, we describe these critical points by discussing recent literature data and our research experience.
Citations
Citations to this article as recorded by
Evaluating short-term and long-term liver fibrosis improvement in hepatitis C patients after DAA treatment Yifan Wang, Xinyan Ma, Yanzheng Zou, Ming Yue, Meiling Zhang, Rongbin Yu, Hongbo Chen, Peng Huang The Journal of Biomedical Research.2024; 38(5): 464. CrossRef
Laboratory Biochemical and Hematological Parameters: Early Predictive Biomarkers for Diagnosing Hepatitis C Virus Infection Saeede Bagheri, Ghazaleh Behrouzian Fard, Nasrin Talkhi, Davoud Rashidi Zadeh, Naser Mobarra, Seyedmahdi Mousavinezhad, Fatemeh Mirzaeian Khamse, Mahdi Hosseini Bafghi Journal of Clinical Laboratory Analysis.2024;[Epub] CrossRef
Differences in HCV Seroprevalence, Clinical Features, and Treatment Outcomes between Female and Male Incarcerated Population: Results from a Matched Cohort Study Vito Fiore, Andrea De Vito, Elena Rastrelli, Valentina Manca, Giuseppe De Matteis, Roberto Ranieri, Emanuele Pontali, Nicholas Geremia, Sandro Panese, Giulio Starnini, Giordano Madeddu, Sergio Babudieri Viruses.2023; 15(12): 2414. CrossRef
Similarities, differences, and possible interactions between hepatitis E and hepatitis C viruses: Relevance for research and clinical practice Nadia Marascio, Salvatore Rotundo, Angela Quirino, Giovanni Matera, Maria Carla Liberto, Chiara Costa, Alessandro Russo, Enrico Maria Trecarichi, Carlo Torti World Journal of Gastroenterology.2022; 28(12): 1226. CrossRef
HCV inhibits M2a, M2b and M2c macrophage polarization via HCV core protein engagement with Toll‑like receptor 2 Shixing Zhao, Meng Si, Xianpei Deng, Dengqin Wang, Lingbin Kong, Qianqian Zhang Experimental and Therapeutic Medicine.2022;[Epub] CrossRef
Circulating Genotypes of Hepatitis C Virus in Italian Patients before and after the Application of Wider Access Criteria to HCV Treatment Daniela Zago, Irene Pozzetto, Monia Pacenti, Giuseppina Brancaccio, Silvia Ragolia, Monica Basso, Saverio Giuseppe Parisi The Open Microbiology Journal.2022;[Epub] CrossRef
The Role of the Microbiota Gut–Liver Axis during HCV Chronic Infection: A Schematic Overview Nadia Marascio, Carmen De Caro, Angela Quirino, Maria Mazzitelli, Emilio Russo, Carlo Torti, Giovanni Matera Journal of Clinical Medicine.2022; 11(19): 5936. CrossRef
Epidemiology and Genotype Distribution of Hepatitis C Virus in Russia Nikolay Pimenov, Dmitry Kostyushev, Svetlana Komarova, Anastasia Fomicheva, Alexander Urtikov, Olga Belaia, Karina Umbetova, Olga Darvina, Natalia Tsapkova, Vladimir Chulanov Pathogens.2022; 11(12): 1482. CrossRef
Immunological Mechanisms for Hepatocellular Carcinoma Risk after Direct-Acting Antiviral Treatment of Hepatitis C Virus Infection Pil Soo Sung, Eui-Cheol Shin Journal of Clinical Medicine.2021; 10(2): 221. CrossRef
Effect of directly acting antivirals for hepatitis C virus infection on proprotein convertase subtilisin/kexin type 9 level Carlo Torti, Vincenzo Scaglione, Bruno Mario Cesana, Chiara Costa, Nadia Marascio, Elisabetta Schiaroli, Chiara Busti, Sabrina Bastianelli, Maria Mazzitelli, Enrico Maria Trecarichi, Daniela Francisci Health Science Reports.2021;[Epub] CrossRef
Resistance-associated substitutions and response to treatment in a chronic hepatitis C virus infected-patient: an unusual virological response case report Fabián Aldunate, Natalia Echeverría, Daniela Chiodi, Pablo López, Adriana Sánchez-Cicerón, Martín Soñora, Juan Cristina, Gonzalo Moratorio, Nelia Hernández, Pilar Moreno BMC Infectious Diseases.2021;[Epub] CrossRef
Phylogenetic and Molecular Analyses of More Prevalent HCV1b Subtype in the Calabria Region, Southern Italy Nadia Marascio, Angela Costantino, Stefania Taffon, Alessandra Lo Presti, Michele Equestre, Roberto Bruni, Giulio Pisani, Giorgio Settimo Barreca, Angela Quirino, Enrico Maria Trecarichi, Chiara Costa, Maria Mazzitelli, Francesca Serapide, Giovanni Matera Journal of Clinical Medicine.2021; 10(8): 1655. CrossRef
Interferon Response in Hepatitis C Virus-Infected Hepatocytes: Issues to Consider in the Era of Direct-Acting Antivirals Pil Soo Sung, Eui-Cheol Shin International Journal of Molecular Sciences.2020; 21(7): 2583. CrossRef
HCV Antibody Prevalence and Genotype Evolution in a Teaching Hospital, Calabria Region, Southern Italy Over A Decade (2008-2018) Nadia Marascio, Maria Mazzitelli, Giuseppe G.M. Scarlata, Aida Giancotti, Giorgio S. Barreca, Angelo G. Lamberti, Francesca Divenuto, Chiara Costa, Enrico M. Trecarichi, Giovanni Matera, Maria C. Liberto, Carlo Torti The Open Microbiology Journal.2020; 14(1): 84. CrossRef
microRNA-99a Restricts Replication of Hepatitis C Virus by Targeting mTOR and De Novo Lipogenesis Eun Byul Lee, Pil Soo Sung, Jung-Hee Kim, Dong Jun Park, Wonhee Hur, Seung Kew Yoon Viruses.2020; 12(7): 696. CrossRef
Dissimilar Conservation Pattern in Hepatitis C Virus Mutant Spectra, Consensus Sequences, and Data Banks Carlos García-Crespo, María Eugenia Soria, Isabel Gallego, Ana Isabel de Ávila, Brenda Martínez-González, Lucía Vázquez-Sirvent, Jordi Gómez, Carlos Briones, Josep Gregori, Josep Quer, Celia Perales, Esteban Domingo Journal of Clinical Medicine.2020; 9(11): 3450. CrossRef
Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals Hye Won Lee, Dai Hoon Han, Hye Jung Shin, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Cancers.2020; 12(11): 3414. CrossRef
The remaining challenges of HCV treatment in the direct‐acting antivirals era Beom Kyung Kim, Sang Hoon Ahn Journal of Gastroenterology and Hepatology.2019; 34(11): 1891. CrossRef
The advent of novel, direct-acting antiviral (DAA) regimens for hepatitis C viral (HCV) infection has revolutionized its treatment by producing a sustained virologic response of more than 95% with few side effects and no comorbidities in the general population. Until recently, ideal DAA regimens have not been available to patients with severe renal impairment and end-stage renal disease because there are limited data on the pharmacokinetics, safety, and efficacy of treatment in this unique population. In a hemodialysis context, identifying patients in need of treatment and preventing HCV transmission may also be a matter of concern. Recently published studies suggest that a combination of paritaprevir/ ritonavir/ombitasvir and dasabuvir, elbasvir/grazoprevir, or glecaprevir/pibrentasir successfully treats HCV infection in chronic kidney disease stage 4 or 5 patients with or without hemodialysis.
Citations
Citations to this article as recorded by
The remaining challenges of HCV treatment in the direct‐acting antivirals era Beom Kyung Kim, Sang Hoon Ahn Journal of Gastroenterology and Hepatology.2019; 34(11): 1891. CrossRef
The current standard of care for patients with chronic hepatitis C virus (HCV) infection is a combination of direct-acting antiviral agents (DAAs). Most HCV patients treated with these drugs achieve viral elimination, but 1% to 15% fail to attain this objective . Treatment failures are usually related to relapse, and less often to on-treatment viral breakthrough. HCV drug resistant associated substitutions are detected in most patients who do not eliminate the virus. The risk of developing these variants depends on host- and virus-related factors, the properties of the drugs used, and the treatment strategies applied. Patients who carry Resistant Associated Substitutions (RASs) may not obtain benefits from treatment, and are at a risk of disease progression. Whether HCV RASs persist depends on their type: NS3-4A variants often disappear gradually after DAA therapy is stopped, whereas NS5A variants tend to persist for more than 2 years. The best way to prevent emergence of resistant variants is to eliminate the virus at the first treatment using highly potent DAAs with genetic barriers to resistance. For those who fail an NS5A inhibitor, deferral of treatment is recommended pending the availability of additional data if they do not have cirrhosis or reasons for urgent re-treatment. If re-treatment is needed, the most commonly used strategy is sofosbuvir as backbone therapy plus a drug from a class other than that previously used, for 24 weeks. Unless it is contraindicated, weight-based ribavirin should also be added. If available, nucleotide-based (eg, sofosbuvir) triple or quadruple DAA regimens may be considered. The optimal treatment for patients who fail an NS5A inhibitor and those with multidrug-resistant variants remains to be defined, and research efforts should continue to focus on treatment for these patients.
Effectiveness and safety of SOF/VEL containing rescue therapy in treating chronic HCV-GT4 patients previously failed NS5A inhibitors-based DAAs Heba Omar, Mohammed Hamdy Abdel Maksoud, Ahmed A. Goma, Essam A. Hassan, Nancy Abdalla Atta, Mahmoud Khalil, Mohamed Soliman Hegazy, Samy Zaky, Gamal Esmat Egyptian Liver Journal.2024;[Epub] CrossRef
High efficacy and safety of direct‐acting antivirals for the treatment of chronic hepatitis C: A cohort study conducted in Vietnam Thong Duy Vo, Van Thi Thu Bui, Huong Tu Lam, Quynh Thi Huong Bui Pharmacology Research & Perspectives.2024;[Epub] CrossRef
Is there a connection between neurocognitive profile in treatment naïve non-cirrhotic HCV patients and level of systemic inflammation? Maja Ružić, Natalija Rajić, Željka Nikolašević, Aleksandar Spasić, Maria Pete, Vojislava Bugarski Ignjatović Journal of NeuroVirology.2023; 29(6): 723. CrossRef
Fatores associados à adesão ao tratamento da hepatite C: revisão integrativa Layla Tatiane Côco, Giovanni Faria Silva, Fernando Gomes Romeiro, Ana Teresa de Abreu Ramos Cerqueira Ciência & Saúde Coletiva.2022; 27(4): 1359. CrossRef
Direct-acting antiviral retreatment patterns for hepatitis C Shaquib Al Hasan, Daniel G Dauner, Abhijeet Rajpurohit, Joel F Farley Journal of Managed Care & Specialty Pharmacy.2022; 28(10): 1100. CrossRef
Hepatitis C Resistance-Associated Substitutions Among People Who Inject Drugs Treated With Direct-Acting Antiviral-Containing Regimens Matthew J Akiyama, Lindsey Riback, Jacqueline D Reeves, Yolanda S Lie, Linda Agyemang, Brianna L Norton, Julia H Arnsten, Alain H Litwin Open Forum Infectious Diseases.2021;[Epub] CrossRef
Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials Edward Gane, Victor de Ledinghen, Douglas E. Dylla, Giuliano Rizzardini, Mitchell L. Shiffman, Stephen T. Barclay, Jose Luis Calleja, Zhenyi Xue, Margaret Burroughs, Julio A. Gutierrez Journal of Viral Hepatitis.2021; 28(11): 1635. CrossRef
Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first‐ and second‐generation NS5A inhibitors Sergii V. Fedorchenko, Tatiana Martynovych, Zhanna Klimenko, Iryna Solianyk Journal of Medical Virology.2021; 93(8): 4975. CrossRef
Provider Perceptions of Hepatitis C Treatment Adherence and Initiation Grace Zhang, Krupa Patel, Akshata Moghe, Andrea Reid, Marina Serper, Linda Calgaro, Sandra Gibson, Susan Zickmund, Obaid Shaikh, Shari Rogal Digestive Diseases and Sciences.2020; 65(5): 1324. CrossRef
Long-chain fatty acyl-coenzyme A suppresses hepatitis C virus infection by targeting virion-bound lipoproteins Xinlei Li, Jinqian Li, Yetong Feng, Hua Cai, Yi-Ping Li, Tao Peng Antiviral Research.2020; 177: 104734. CrossRef
Simple predictors of nonresponse to direct-acting antivirals in chronic hepatitis C patients Hend Ibrahim Shousha, Yasmin Saad, Doa’a A. Saleh, Hosam Dabes, Magdy Alserafy, Yehia ElShazly, Mohamed Said European Journal of Gastroenterology & Hepatology.2020; 32(8): 1017. CrossRef
Real‐world safety and effectiveness of retreatment of Egyptian chronic hepatitis C patients not responding to NS5A inhibitor‐based therapies Monkez M. Yousif, Hussien Ahmed, Hany M. Elsadek, Ali M. shendi, Tamer M. Gouda, Islam A. Elsayed, Mohamed A. Gendia, Mahmoud M. Magdy, Nevin F. lbrahim, Ayman M. E. M. Sadek, Ayman M. Zaki, Hamdy Shafeik, Mahmoud H. Zahran Journal of Viral Hepatitis.2020; 27(11): 1190. CrossRef
Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes Vanessa D. Costa, Carlos E. Brandão-Mello, Estevão P. Nunes, Pedro Guilherme Corôa dos Santos Silva, Lia Laura Lewis Ximenez de Souza Rodrigues, Elisabeth Lampe, Francisco Campello do Amaral Mello, Tatsuo Kanda PLOS ONE.2019; 14(5): e0216327. CrossRef
New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials Valentina Pecoraro, Rita Banzi, Elisabetta Cariani, Johanna Chester, Erica Villa, Roberto D'Amico, Vittorio Bertele', Tommaso Trenti Journal of Clinical and Experimental Hepatology.2019; 9(4): 522. CrossRef
Tolerability and effectiveness of generic direct‐acting antiviral drugs in eradication of hepatitis C genotype 4 among Egyptian patients Sameh A. Lashen, Mohammed M. Shamseya, Marwa A. Madkour, Galal A. Aboufarrag Liver International.2019; 39(5): 835. CrossRef
Prevalence of baseline NS3 resistance-associated substitutions (RASs) on treatment with protease inhibitors in patients infected with HCV genotype 1 Vanessa Duarte Costa, Nathália Delvaux, Carlos Eduardo Brandão-Mello, Estevão Portela Nunes, Paulo Sérgio Fonseca de Sousa, Lia Laura Lewis Ximenez de Souza Rodrigues, Elisabeth Lampe, Francisco Campello do Amaral Mello Clinics and Research in Hepatology and Gastroenterology.2019; 43(6): 700. CrossRef
Resistance Mutations A30K and Y93N Associated with Treatment Failure with Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection Non-Responder Patients: Case Reports Vanessa D. Costa, Patricia Pellegrini, Vivian Rotman, Ana Maria Pittella, Estevão P. Nunes, Barbara V. Lago, Elisabeth Lampe, Francisco C. A. Mello Viruses.2019; 11(11): 1004. CrossRef
Development of Duodenal Ulcers due to the Discontinuation of Proton Pump Inhibitors After the Induction of Sofosbuvir Plus Ledipasvir Therapy: A Report of Two Cases S. Miuma, H. Miyaaki, Y. Miyazoe, T. Suehiro, R. Sasaki, H. Shibata, N. Taura, K. Nakao Transplantation Proceedings.2018; 50(1): 222. CrossRef
Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients Adel Abdel-Moneim, Alaa Aboud, Mohamed Abdel-Gabbar, Mohamed Zanaty, Mohamed Ramadan Digestive Diseases and Sciences.2018; 63(5): 1341. CrossRef
A sofosbuvir-based quadruple regimen is highly effective in HCV type 4-infected Egyptian patients with DAA treatment failure Adel Abdel-Moneim, Alaa Aboud, Mohamed Abdel-Gabbar, Mohamed I. Zanaty, Mohamed Ramadan Journal of Hepatology.2018; 68(6): 1313. CrossRef
The outcome of combined treatment with ombitasvir-paritaprevir-ritonavir, sofosbuvir with or without ribavirin as salvage therapy for Egyptian HCV experienced patients: A single center study Waleed Abdelfattah Ismail, Fady Maher Wadea Drug Discoveries & Therapeutics.2018; 12(6): 368. CrossRef
Interaction between Galectin-9/TIM-3 pathway and follicular helper CD4+ T cells contributes to viral persistence in chronic hepatitis C Ya Zhuo, Yi-Fu Zhang, Hong-Jie Wu, Lei Qin, Yan-Ping Wang, A-Min Liu, Xin-Hong Wang Biomedicine & Pharmacotherapy.2017; 94: 386. CrossRef
Treatment of Chronic Hepatitis C Patients Who Do Not Respond to Direct Acting Antivirals Jeong Han Kim The Korean Journal of Gastroenterology.2017; 70(2): 111. CrossRef
Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection Nancy Reau, Michael N. Robertson, Hwa‐Ping Feng, Luzelena Caro, Wendy W. Yeh, Bach‐Yen T. Nguyen, Janice Wahl, Eliav Barr, Peggy Hwang, Stephanie O. Klopfer Hepatology Communications.2017; 1(8): 757. CrossRef
Hepatitis C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030 Mark W Sonderup, Mary Afihene, Reidwaan Ally, Betty Apica, Yaw Awuku, Lina Cunha, Geoffrey Dusheiko, Neliswa Gogela, Marie-Jeanne Lohouès-Kouacou, Phillip Lam, Olufunmilayo Lesi, Papa Saliou Mbaye, Emmanuel Musabeyezu, Betty Musau, Olesegun Ojo, John Rweg The Lancet Gastroenterology & Hepatology.2017; 2(12): 910. CrossRef
Retreatment Options Following HCV Direct-Acting Antiviral Failure Autumn Zuckerman, Cody A. Chastain, Susanna Naggie Current Treatment Options in Infectious Diseases.2017; 9(4): 389. CrossRef
Avasimibe: A novel hepatitis C virus inhibitor that targets the assembly of infectious viral particles Longbo Hu, Jinqian Li, Hua Cai, Wenxia Yao, Jing Xiao, Yi-Ping Li, Xiu Qiu, Huimin Xia, Tao Peng Antiviral Research.2017; 148: 5. CrossRef
Background/Aims The treatment strategy for hepatitis C virus (HCV) has been changing rapidly since the introduction of direct-acting antivirals such as daclatasvir (DCV) and asunaprevir (ASV). We evaluated the efficacy and safety of DCV and ASV for HCV in real-life practice.
Methods Patients were treated with 60 mg of DCV once daily plus 200 mg of ASV twice daily for 24 weeks, and followed for 12 weeks. The primary endpoint was a sustained virological response at 12 weeks after treatment (SVR12) and safety.
Results This retrospective study included eight patients with chronic HCV genotype 1b infection. All of the enrolled patients were diagnosed with liver cirrhosis, and their mean age was 65.75 years. One patient was a nonresponder and two patients relapsed with previous pegylated interferon (PegIFN) and ribavirin (RBV) treatment. None of the patient showed NS5A mutation. An SVR12 was achieved in 88% of cases by the DCV and ASV combination therapy. The serum transaminase level and the aspartate-aminotransferase-to-platelet ratio were improved after the treatment. DCV and ASV were well tolerated in most of the patients, with treatment discontinuation due to adverse events (elevated liver enzyme and decompensation) occurring in two patients.
Conclusions In this study, combination of DCV and ASV treatment achieved a high sustained virological response with few adverse events even in those with cirrhosis, advanced age, and nonresponse/relapse to previous interferon-based therapy. Close monitoring of safety issues may be necessary when treating chronic HCV patients receiving DCV and ASV, especially in older patient and those with cirrhosis.
Citations
Citations to this article as recorded by
Clinical outcomes after the introduction of direct antiviral agents for patients infected with genotype 1b hepatitis C virus depending on the regimens: A multicenter study in Korea Jung Hyun Kwon, Sun Hong Yoo, Soon Woo Nam, Hee Yeon Kim, Chang Wook Kim, Chan Ran You, Sang Wook Choi, Se Hyun Cho, Joon‐Yeol Han, Do Seon Song, U Im Chang, Jin Mo Yang, Sung Won Lee, Hae Lim Lee, Nam Ik Han, Seok‐Hwan Kim, Myeong Jun Song, Pil Soo Sung, Journal of Medical Virology.2019; 91(6): 1104. CrossRef
Real‐life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: An emphasis on the pretreatment NS5A resistance‐associated substitution test Eun Sun Jang, Kyung‐Ah Kim, Young Seok Kim, In Hee Kim, Byung Seok Lee, Youn Jae Lee, Woo Jin Chung, Sook‐Hyang Jeong Journal of Medical Virology.2019; 91(12): 2158. CrossRef
An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection Youn Jae Lee, Jeong Heo, Do Young Kim, Woo Jin Chung, Won Young Tak, Yoon Jun Kim, Seung Woon Paik, Eungeol Sim, Susila Kulasingam, Rohit Talwani, Barbara Haber, Peggy Hwang Clinical and Molecular Hepatology.2019; 25(4): 400. CrossRef
Early development of de novo hepatocellular carcinoma after direct‐acting agent therapy: Comparison with pegylated interferon‐based therapy in chronic hepatitis C patients S. H. Yoo, J. H. Kwon, S. W. Nam, H. Y. Kim, C. W. Kim, C. R. You, S. W. Choi, S. H. Cho, J.‐Y. Han, D. S. Song, U. I. Chang, J. M. Yang, H. L. Lee, S. W. Lee, N. I. Han, S.‐H. Kim, M. J. Song, S. Hwang, P. S. Sung, J. W. Jang, S. H. Bae, J. Y. Choi, S. K Journal of Viral Hepatitis.2018; 25(10): 1189. CrossRef
Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C Isabella Esposito, Sebastián Marciano, Julieta Trinks Expert Opinion on Drug Metabolism & Toxicology.2018; 14(6): 649. CrossRef
Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study Byeong Wook Cho, Seok Bae Kim, Il Han Song, Sae Hwan Lee, Hong Soo Kim, Tae Hee Lee, Young Woo Kang, Seok Hyun Kim, Byung Seok Lee, Hee Bok Chae Clinical and Molecular Hepatology.2017; 23(1): 51. CrossRef
Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis Seyed Moayed Alavian, Mohammad Saeid Rezaee-Zavareh Hepatitis Monthly.2016;[Epub] CrossRef
First
Prev
